<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of restless legs syndrome and periodic limb movement disorder in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of restless legs syndrome and periodic limb movement disorder in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of restless legs syndrome and periodic limb movement disorder in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael H Silber, MBChB
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Howard I Hurtig, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alon Y Avidan, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1662077">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Restless legs syndrome (RLS) refers to an urge to move the legs, usually associated with unpleasant sensations. The urge to move the legs is worse at rest and at night and is relieved by movement. RLS is commonly associated with sleep disturbance and with involuntary, jerking movements of the legs during sleep, known as periodic limb movements of sleep (PLMS). When significant sleep disturbances or impaired daytime functioning coexist with PLMS in the absence of RLS or other associated disorders, the term periodic limb movement disorder (PLMD) is used.
        </p>
        <p>
         RLS is a treatable condition that generally responds well to pharmacologic therapy. A variety of treatments have been studied in randomized, controlled trials; the major classes of drugs used include alpha-2-delta voltage-gated calcium channel ligands, dopaminergic agents, opioids, and benzodiazepines [
         <a href="#rid1">
          1-4
         </a>
         ]. The treatment approach to PLMD is similar to that of RLS, although supported by considerably less data. (See
         <a class="local">
          'Periodic limb movement disorder'
         </a>
         below.)
        </p>
        <p>
         The selection of therapy depends upon a number of factors, including disease severity, patient age, comorbidities (eg, pain, depression, anxiety, history of impulse control disorders), drug side effects, and patient preferences. The goals of therapy are to reduce or eliminate symptoms of RLS and improve daytime function, sleep, and quality of life.
        </p>
        <p>
         This topic will review the treatment of RLS and PLMD in nonpregnant adults. The clinical features and diagnosis of RLS and PLMD in adults and treatment of these disorders in children and pregnant patients are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4892.html" rel="external">
          "Clinical features and diagnosis of restless legs syndrome and periodic limb movement disorder in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98366.html" rel="external">
          "Restless legs syndrome during pregnancy and lactation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16995.html" rel="external">
          "Restless legs syndrome and periodic limb movement disorder in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1663765">
         <span class="h1">
          IRON REPLACEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iron replacement is suggested in patients with restless legs syndrome (RLS) whose fasting serum ferritin level is ≤75 ng/mL  (
         <a class="graphic graphic_algorithm graphicRef131282" href="/z/d/graphic/131282.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid5">
          5-7
         </a>
         ]. As serum ferritin is an acute phase reactant, transferrin saturation (TSAT) less than 20 percent may be a more accurate measure of low iron stores in patients with acute or chronic inflammatory disorders [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3028348378">
         <span class="h2">
          Pretreatment considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iron status is determined by measuring an early morning, fasting iron panel (serum ferritin, iron, total iron-binding capacity, and percentage TSAT). (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Iron studies (list of available tests)'
         </a>
         .)
        </p>
        <p>
         Iron therapy should not be prescribed empirically for RLS because it may result in iron overload, especially in patients with previously unsuspected hemochromatosis. Patients with evidence of iron excess (eg, TSAT ≥45 percent) should not be given a trial of iron. (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis"
         </a>
         .)
        </p>
        <p>
         Importantly, any adult with iron deficiency (eg, serum ferritin level &lt;30 ng/mL) should be evaluated for the underlying cause, which may include gastrointestinal blood loss, especially for adults over 40 to 50 years, or a condition that interferes with iron absorption. (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Search for source of blood and iron loss'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1326236992">
         <span class="h2">
          Administration of iron
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iron supplementation can be supplied orally or intravenously (IV). IV delivery has the advantage of replenishing iron stores with fewer administrations than oral therapy, but it is less convenient and carries a low risk of serious infusion reactions, including anaphylaxis with some formulations. There are no direct comparisons of IV versus oral iron supplementation in patients with RLS, and available data do not show clear superiority of one route of administration over the other.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral iron
         </strong>
         – For most patients, because oral iron is easier to administer and safer, we suggest initial therapy with an oral regimen such as
         <a class="drug drug_general" data-topicid="8444" href="/z/d/drug information/8444.html" rel="external">
          ferrous sulfate
         </a>
         (325 mg orally once daily or once every second day, preferably before bed) [
         <a href="#rid5">
          5,7
         </a>
         ]. In RLS trials, iron has been combined with
         <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">
          vitamin C
         </a>
         (100 to 200 mg with each dose of ferrous sulfate) or a small glass of orange juice [
         <a href="#rid6">
          6
         </a>
         ]. Whether vitamin C improves oral iron absorption is not known, however, and some experts do not advise patients to take vitamin C. Iron should not be taken at the same time as calcium supplements or significant amounts of dairy products. The administration of oral iron and strategies to improve tolerability, including use of every-other-day dosing, are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">
          "Treatment of iron deficiency anemia in adults", section on 'Dosing and administration (oral iron)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          IV iron
         </strong>
         – IV iron therapy is generally reserved for patients with a serum ferritin ≤100 ng/mL, TSAT &lt;45 percent, and either a malabsorption state, complete intolerance to oral iron preparations, moderate to severe symptoms despite a trial of oral iron, or the need for a more rapid response due to severity of symptoms [
         <a href="#rid6">
          6,7
         </a>
         ]. Trials of IV iron suggest that it is effective in approximately 40 to 60 percent of patients selected for therapy [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A number of IV iron preparations are available, with major differences in cost, formulary/purchasing agreements, and number of visits/time required to administer the full dose. If
         <a class="drug drug_general" data-topicid="90237" href="/z/d/drug information/90237.html" rel="external">
          ferric carboxymaltose
         </a>
         is selected, trials in patients with RLS suggest that a total dose of 1000 mg, not 500 mg, should be given. We administer as a single infusion (over 10 to 15 minutes) or in two doses of 500 mg at five- to seven-day intervals [
         <a href="#rid7">
          7
         </a>
         ]. If low molecular weight
         <a class="drug drug_general" data-topicid="8574" href="/z/d/drug information/8574.html" rel="external">
          iron dextran
         </a>
         is used, a test dose of 25 mg should be administered first, followed by 975 mg infused over one hour in normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">
          "Treatment of iron deficiency anemia in adults", section on 'Intravenous iron'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who respond adequately to IV iron but then have recurrent symptoms, repeated infusions can be given in at least 12-week intervals as long as serum ferritin concentration is below 300 ng/mL and TSAT is &lt;45 percent [
         <a href="#rid7">
          7
         </a>
         ]. For patients with a questionable response, we suggest a second infusion before assuming futility, especially if the serum ferritin is still less than 100 ng/mL.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2987956569">
         <span class="h2">
          Response and monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms of RLS usually respond slowly to oral iron, and maximal symptomatic improvement can take several months after the start of oral iron. The response to IV iron is faster, and many patients respond within several days of infusion, particularly those with iron deficiency. Clinical response may be delayed for up to six weeks, however, for reasons that are uncertain [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         We repeat an iron panel after three to four months of therapy and then every three to six months until the serum ferritin level is &gt;100 ng/mL and iron saturation is greater than 20 percent [
         <a href="#rid7">
          7
         </a>
         ]. Monitoring is important to avoid the rare but serious complication of iron overload in patients with hemochromatosis genes [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
         Iron therapy can be discontinued when target values are reached if an ongoing cause for iron deficiency has not been established. The etiologic evaluation of iron deficiency in adults is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Search for source of blood and iron loss'
         </a>
         .)
        </p>
        <p>
         Patients who do not respond symptomatically to iron despite replete iron stores should be considered for pharmacotherapy. (See
         <a class="local">
          'Chronic persistent symptoms'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1180003376">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iron repletion as a treatment for RLS has been studied in patients with and without iron deficiency anemia. The rationale for iron in patients without frank iron deficiency anemia is based on the theory that a deficit in central brain iron exists in RLS despite low-normal or normal peripheral iron stores. Small trials have shown that both anemic and non-anemic patients may respond to iron, and the severity of iron deficiency is not a strong predictor of response.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral iron
         </strong>
         – Supportive evidence for oral iron includes results of a 12-week randomized trial in which 18 adults with RLS and a serum ferritin ≤75 ng/mL (median 37 to 41 ng/mL) were randomly assigned to receive
         <a class="drug drug_general" data-topicid="8444" href="/z/d/drug information/8444.html" rel="external">
          ferrous sulfate
         </a>
         325 mg twice daily or placebo [
         <a href="#rid12">
          12
         </a>
         ]. At 12 weeks, mean International Restless Leg Syndrome Study Group rating scale (IRLS) scores decreased more with iron than placebo (improvement from baseline, 10.4 versus 1.1 points). An earlier trial of oral iron in 28 patients who were not selected based on serum ferritin (median 101 to 135 ng/mL) did not demonstrate a benefit [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          IV iron
         </strong>
         – A variety of IV iron formulations have been studied in RLS, including
         <a class="drug drug_general" data-topicid="90237" href="/z/d/drug information/90237.html" rel="external">
          ferric carboxymaltose
         </a>
         (FCM) [
         <a href="#rid8">
          8,9,14-16
         </a>
         ],
         <a class="drug drug_general" data-topicid="8574" href="/z/d/drug information/8574.html" rel="external">
          iron dextran
         </a>
         [
         <a href="#rid17">
          17
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9004" href="/z/d/drug information/9004.html" rel="external">
          iron sucrose
         </a>
         [
         <a href="#rid18">
          18,19
         </a>
         ]. Results have been inconsistent, and a 2019 meta-analysis that included four of the trials found insufficient evidence to conclude whether iron is beneficial for treatment of RLS based on significant heterogeneity in the formulation of iron used, patient characteristics, and measurement of outcome variables across studies [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among formulations, FCM has been studied in five trials [
         <a href="#rid8">
          8,9,14-16
         </a>
         ], three of which showed statistically significant improvements in RLS symptoms compared with placebo in patients with varying baseline ferritin levels [
         <a href="#rid14">
          14-16
         </a>
         ]. One of the negative trials used a lower dose of FCM (500 mg), which was felt to be inadequate [
         <a href="#rid9">
          9
         </a>
         ]. A trial published subsequent to the 2019 meta-analysis was the first to restrict enrollment to patients with iron deficiency anemia; in this trial, patients randomly assigned to FCM (1500 mg total dose) had improved IRLS scores compared with placebo at six weeks (improvement from baseline, 13.5 versus 1.4 points) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1663800">
         <span class="h1">
          NONPHARMACOLOGIC THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with mild symptoms, nonpharmacologic therapies may be sufficient for symptom relief. In patients with more severe symptoms, nonpharmacologic measures are worth reviewing, as they may limit medication requirements.
        </p>
        <p class="headingAnchor" id="H797281716">
         <span class="h2">
          Behavioral strategies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of the following interventions is supported primarily on the basis of clinical experience and, in some cases, small, randomized trials  (
         <a class="graphic graphic_table graphicRef138393" data-inline-graphics="138393" href="/z/d/graphic/138393.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid7">
          7,20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mental alerting activities, such as working on a computer or doing crossword puzzles, at times of rest or boredom [
         <a href="#rid21">
          21
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoidance of aggravating factors, including consideration of withdrawal of possibly predisposing medications  (
         <a class="graphic graphic_table graphicRef88603" href="/z/d/graphic/88603.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Avoidance of aggravating factors'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate regular exercise [
         <a href="#rid22">
          22
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A trial of abstinence from caffeine and alcohol
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For symptomatic relief – walking, bicycling, soaking the affected limbs, and leg massage, including pneumatic compression [
         <a href="#rid23">
          23
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Short daily hemodialysis for patients with end-stage kidney disease (see
         <a class="medical medical_review" href="/z/d/html/16197.html" rel="external">
          "Sleep disorders in end-stage kidney disease", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1663814">
         <span class="h2">
          Avoidance of aggravating factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Insufficient sleep
         </strong>
         – Sleep deprivation is known to aggravate symptoms of restless legs syndrome (RLS) in many patients, and general principles of sleep hygiene should be reviewed. An approach to the evaluation and behavioral management of insufficient sleep is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/97866.html" rel="external">
          "Insufficient sleep: Evaluation and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evaluation and treatment of other causes of sleep disruption and poor quality sleep, including comorbid sleep disorders such as obstructive sleep apnea (OSA), is also indicated, as treatment may possibly improve RLS symptoms [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medication side effects
         </strong>
         – Antidepressants, neuroleptic agents, dopamine-blocking antiemetics such as
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          metoclopramide
         </a>
         , and sedating antihistamines (including those found in nonprescription medications) may contribute to emergence of RLS or worsening of prior symptoms  (
         <a class="graphic graphic_table graphicRef88603" href="/z/d/graphic/88603.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid25">
          25
         </a>
         ]. Most antidepressant classes have been associated with RLS, including tricyclics, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If antidepressants are necessary, the symptoms of secondary RLS can usually be treated in the same way as primary RLS.
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          Bupropion
         </a>
         is an alternative antidepressant that may be less likely to induce or worsen RLS [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3212212459">
         <span class="h2">
          Complementary and alternative therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of complementary and alternative medical therapies have been reported to have benefits for RLS but the quality of the evidence is low and the number of trials supporting any single therapy is low [
         <a href="#rid28">
          28
         </a>
         ]. Yoga and acupuncture are low-risk strategies that may have some benefit.
        </p>
        <p class="headingAnchor" id="H2700116398">
         <span class="h2">
          Neurostimulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of noninvasive neurostimulation or neuromodulation techniques are under investigation, which may be an option in patients who cannot tolerate medications or who desire a nonpharmacologic approach. One such device, tonic motor activation (TOMAC), delivers bilateral peroneal nerve stimulation via bilateral therapy units worn externally just below the knee, over the head of the fibula [
         <a href="#rid29">
          29
         </a>
         ]. Patients may wear the device in 30-minute sessions whenever they have distressing RLS symptoms (usually around bedtime) for a maximum of 120 minutes per day. The device received marketing approval from the US Food and Drug Administration in April 2023 [
         <a href="#rid29">
          29
         </a>
         ], and the company hopes to have the device available for patients in the United States by 2024.
        </p>
        <p>
         In a randomized sham-controlled trial of TOMAC in 133 patients with medication-refractory RLS, the Clinical Global Impressions-Improvement (CGI-I) responder rate at four weeks (defined as having been rated by the clinician as much or very much improved) was greater in the active TOMAC group compared with the sham group (45 versus 16 percent) [
         <a href="#rid30">
          30
         </a>
         ]. Mean International Restless Leg Syndrome Study Group rating scale (IRLS) scores from baseline to week 4 also improved (mean difference between groups -3.4 points [95% CI -1.4 to -5.4]). The device was safe and well tolerated, with no serious or severe adverse events; the most common adverse effects were local discomfort (28 percent) and administration site irritation (9 percent). Open-label follow-up revealed sustained benefits and no new safety signals at 24 weeks [
         <a href="#rid31">
          31
         </a>
         ]. There are no published data yet available in patients with mild or previously untreated RLS; these studies were performed in patients with moderate-to-severe RLS refractory to at least one medication.
        </p>
        <p class="headingAnchor" id="H1256864172">
         <span class="h1">
          INTERMITTENT SYMPTOMS
         </span>
        </p>
        <p class="headingAnchor" id="H1660503712">
         <span class="h2">
          Choice of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with intermittent symptoms (troublesome enough to require treatment but occurring less than twice per week on average), nonpharmacologic therapies may be sufficient for symptom relief. In other patients, clinically significant symptoms do not occur frequently enough to require daily treatment but are nonetheless disabling when they do occur (eg, airplane or lengthy car rides, theater attendance).
        </p>
        <p>
         For intermittent use, medication options for RLS include
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         , a benzodiazepine or benzodiazepine receptor agonist, and a low-dose opioid [
         <a href="#rid7">
          7
         </a>
         ]. Among these, carbidopa-levodopa is the least sedating and therefore preferred for daytime use and when continued alertness is desired. It can also be given before bed or in the middle of the night. Bedtime use of a benzodiazepine or low-dose opioid is also an option, especially in patients with comorbid insomnia. (See
         <a class="local">
          'Carbidopa-levodopa'
         </a>
         below and
         <a class="local">
          'Benzodiazepines'
         </a>
         below and
         <a class="local">
          'Opioids'
         </a>
         below.)
        </p>
        <p>
         Dopamine agonists are seldom used for intermittent RLS because they have a delayed onset of action (usually 90 to 120 minutes) and are less helpful once symptoms have already started.
        </p>
        <p class="headingAnchor" id="H117032376">
         <span class="h2">
          Carbidopa-levodopa
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          Carbidopa-levodopa
         </a>
         was the first drug to be formally studied in RLS, and its ability to ameliorate symptoms of RLS has long been recognized. However, use of carbidopa-levodopa for RLS has waned over time as the risk for augmentation has been better characterized, and as other dopaminergic agents that have a lower risk for augmentation have become available. (See
         <a class="local">
          'Augmentation'
         </a>
         below.)
        </p>
        <p>
         Based on its rapid onset and tolerability at low doses, however,
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         remains a reasonable "on demand" treatment option for patients with intermittent RLS who do not require daily therapy [
         <a href="#rid2">
          2,7,32
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – Levodopa is given in combination with a peripheral decarboxylase inhibitor, most commonly
         <a class="drug drug_general" data-topicid="9200" href="/z/d/drug information/9200.html" rel="external">
          carbidopa
         </a>
         , to block systemic conversion of levodopa to dopamine. For best absorption,
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         should not be taken with high protein foods. Suggested agents include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          Carbidopa-levodopa
         </a>
         25 mg/100 mg, one-half or one tablet, can be used as a starting dose for intermittent RLS that occurs during the evening, at bedtime, or on waking during the night [
         <a href="#rid7">
          7
         </a>
         ]. This medication may be helpful for managing RLS symptoms in an "on demand" fashion, particularly when associated with specific triggers including lengthy travel by automobile or airline, or spectator events with prolonged sitting. Levodopa doses greater than 200 mg per day should be avoided to reduce the risk of augmentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          Carbidopa-levodopa
         </a>
         controlled release (CR), starting at 25 mg/100 mg before bed, may be helpful for RLS symptoms that awaken the patient during the night.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – Short-term therapy with
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         is generally well tolerated; common adverse effects such as nausea, dizziness, and somnolence are usually mild and improve over time. Other problems that may occur in patients on carbidopa-levodopa include symptom rebound in the early morning (20 to 35 percent) or in the second half of the night [
         <a href="#rid33">
          33,34
         </a>
         ]. Carbidopa-levodopa CR combined with standard carbidopa-levodopa may help sleep quality during the second half of the night for patients who experience recurrence [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Several small, randomized studies have demonstrated that
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         improves RLS symptom severity, number of periodic limb movements in sleep (PLMS), self-rated sleep quality, and quality of life compared with placebo [
         <a href="#rid36">
          36
         </a>
         ]. Most studies were performed before the International Restless Leg Syndrome Study Group rating scale (IRLS) became widely used as an outcome measure; in two studies that reported RLS symptom severity on a 10-point scale, levodopa improved symptom severity by a mean of 1.34 points compared with placebo [
         <a href="#rid36">
          36
         </a>
         ]. Carbidopa-levodopa was also effective in a double-blind study of uremic RLS [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H106396430">
         <span class="h2">
          Benzodiazepines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benzodiazepines can be useful in mild cases of RLS, particularly in younger patients [
         <a href="#rid38">
          38,39
         </a>
         ]. The best-studied benzodiazepine in RLS is
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         .
        </p>
        <p>
         In a small, randomized, double-blind, crossover trial, treatment with
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         , 1 mg daily, was superior to placebo in six patients with RLS [
         <a href="#rid40">
          40
         </a>
         ]. In an open trial, 14 of 15 patients with RLS due to uremia responded to clonazepam, 1 to 2 mg daily [
         <a href="#rid41">
          41
         </a>
         ]. Clinical experience suggests that clonazepam is useful in some patients at 0.5 mg daily.
        </p>
        <p>
         Although most trials have been performed with
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         , its long duration of action may result in more adverse effects, such as nocturnal unsteadiness, drowsiness or cognitive impairment in the morning, impotence, and exacerbation of sleep apnea [
         <a href="#rid42">
          42
         </a>
         ]. However, at least one study has shown a low rate of adverse effects from clonazepam in older adult patients [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Long-term maintenance treatment with benzodiazepines is limited by tolerance in many patients, but abuse appears to be low in this disorder. Because of tolerance and the potential for side effects, use of benzodiazepines for RLS is generally limited to those patients that require only intermittent therapy, or as an add-on agent in patients with refractory symptoms.
        </p>
        <p>
         Short-acting nonbenzodiazepine receptor agonists such as
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         can be used intermittently, especially if insomnia related to RLS is a problem. However, sleepwalking and sleep-related eating disorder have been reported with their use in the setting of RLS (as high as 80 percent in one study of 15 patients) [
         <a href="#rid43">
          43-46
         </a>
         ]. This observation is important, as RLS may be misinterpreted as sleep-onset insomnia, increasing the risk for hypnotic-induced parasomnias [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1663828">
         <span class="h1">
          CHRONIC PERSISTENT SYMPTOMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic persistent restless legs syndrome (RLS) is defined as RLS that is frequent and troublesome enough to require daily treatment, with symptoms usually occurring at least twice a week on average and resulting in moderate or severe distress [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1935612">
         <span class="h2">
          Choice of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients with chronic persistent RLS despite replete iron stores and elimination of aggravating factors, we suggest initial therapy with a gabapentinoid (also referred to as alpha-2-delta calcium channel ligands; ie,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         ) rather than a dopamine agonist (
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         ,
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         ). Our preference for gabapentinoids is based on the high frequency of intermediate and long-term augmentation with dopamine agonists, as well as their risk of impulse control disorders [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="local">
          'Augmentation'
         </a>
         below.)
        </p>
        <p>
         A dopamine agonist is a reasonable first-line alternative in patients with increased risk for side effects from gabapentinoids, such as those with obesity and its complications, a past or present history of moderate to severe depression, a disorder causing gait instability or respiratory failure, and a history of substance use disorder  (
         <a class="graphic graphic_algorithm graphicRef131282" data-inline-graphics="131282" href="/z/d/graphic/131282.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef101364" data-inline-graphics="101364" href="/z/d/graphic/101364.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         Multiple agents from both of these classes of drugs have been shown to be more effective than placebo in randomized trials in patients with RLS [
         <a href="#rid1">
          1-3,5,7,48-50
         </a>
         ]. Head-to-head comparisons between the two classes are limited to a single study showing approximate equivalence in effect [
         <a href="#rid49">
          49
         </a>
         ]. A network meta-analysis of 35 trials in 7333 patients with RLS found similar efficacy across all medications examined (
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ,
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         , and
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         ) and little evidence of inter-treatment differences [
         <a href="#rid51">
          51
         </a>
         ]. Unlike dopamine agonists, gabapentinoids do not appear to carry risk of augmentation with long-term use. They may also be helpful for common comorbidities of RLS, such as pain, anxiety, or insomnia.
        </p>
        <p>
         If the first drug chosen is ineffective or poorly tolerated, then a drug of the other class should be tried [
         <a href="#rid7">
          7
         </a>
         ]. Small, randomized trials and observational studies also support the use of other agents for RLS, including levodopa, benzodiazepines, and opioids, but generally these are reserved for intermittent use or in patients with more refractory symptoms. (See
         <a class="local">
          'Intermittent symptoms'
         </a>
         above and
         <a class="local">
          'Refractory RLS'
         </a>
         below.)
        </p>
        <p>
         Patients on continuous therapy should be reassessed regularly (eg, every 6 to 12 months) and screened for side effects and complications such as augmentation, which is a common complication of long-term dopaminergic therapy [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="local">
          'Augmentation'
         </a>
         below.)
        </p>
        <p>
         These recommendations are generally consistent with practice guidelines of the American Academy of Neurology [
         <a href="#rid5">
          5
         </a>
         ], the American Academy of Sleep Medicine [
         <a href="#rid2">
          2
         </a>
         ], and the Restless Legs Syndrome Foundation [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1167751183">
         <span class="h2">
          Gabapentinoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          Pregabalin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , and
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         are all appropriate first-line therapies for chronic persistent RLS in many patients [
         <a href="#rid7">
          7,52,53
         </a>
         ]. The mechanism of action in RLS is unknown.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agent selection
         </strong>
         – We choose among the three drugs based on factors that include pharmacokinetics, symptom pattern, and cost. When RLS symptoms occur predominantly in the evening or night, we start with
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         or
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ; pregabalin is preferred because of straightforward pharmacokinetics and better data on efficacy, but gabapentin is often cheaper and can be substituted if cost is a factor. For patients with RLS symptoms throughout most of the day and night, we prefer
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         because it provided 24-hour coverage with the convenience of once-daily dosing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comorbidities favoring use
         </strong>
         – The gabapentinoids as a class may be particularly useful when RLS occurs in the setting of a painful peripheral neuropathy or an unrelated chronic pain syndrome and in patients with comorbid insomnia or sleep disturbance that is disproportionate to other RLS symptoms [
         <a href="#rid48">
          48
         </a>
         ]. They may also be considered in the treatment of RLS in association with Parkinson disease, since these patients may already be receiving dopaminergic therapy, or as an add-on therapy in patients with a partial response to dopamine agonist therapy but intolerance to higher doses. Unlike the dopamine agonists, they are not associated with augmentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Precautions
         </strong>
         – As with other antiseizure medications, the gabapentinoids may be associated with an increased risk of suicidal thoughts and behavior, and patients should be monitored for emergent suicidality and depression. Other potential side effects, especially in older patients, include mental fogging, dizziness and unsteadiness, weight gain and leg edema. All three drugs in the class are excreted by the kidneys and require dose adjustments for renal dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In December 2019, the US Food and Drug Administration issued a warning about the potential for serious respiratory difficulties when gabapentinoids are used in combination with other central nervous system depressants (eg, opioids, benzodiazepines), especially in older adults and those with respiratory disorders such as severe chronic obstructive pulmonary disease (COPD) [
         <a href="#rid54">
          54
         </a>
         ]. There is also growing awareness of the potential for misuse and abuse of these drugs [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H611245954">
         <span class="h3">
          Pregabalin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          Pregabalin
         </a>
         is chemically similar to
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         and is used clinically as an antiseizure drug and neuropathic pain agent, in addition to its role in RLS.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – We suggest starting
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         at a dose of 50 to 75 mg per day, taken one to two hours before the usual onset of symptoms. The usual effective dose in patients with RLS is 150 to 450 mg per day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – The most common side effects reported with
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         include dizziness, somnolence, fatigue, headache, peripheral edema, and weight gain [
         <a href="#rid49">
          49,56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In the largest of several randomized trials,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         was compared with
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         and placebo in 719 patients with RLS [
         <a href="#rid49">
          49
         </a>
         ]. After 12 weeks of therapy, both pregabalin (300 mg daily) and pramipexole (0.5 mg daily) were associated with a significant 3- to 4-point improvement in International Restless Leg Syndrome Study Group rating scale (IRLS) scores compared with placebo. Over 40 to 52 weeks of treatment, pregabalin was noninferior to pramipexole [
         <a href="#rid51">
          51
         </a>
         ] on measures of efficacy and was associated with a significantly lower augmentation rate (2.1 percent) compared with pramipexole at a dose of 0.25 mg (5.3 percent) or 0.5 mg (7.7 percent). By contrast, pregabalin was associated with a slightly higher rate of treatment discontinuation due to side effects (28 percent, versus 19 and 24 percent for pramipexole 0.25 mg and 0.5 mg daily, respectively). Suicidal ideation was reported in six patients taking pregabalin and in five patients taking pramipexole.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          Pregabalin
         </a>
         may also improve subjective and objective measures of sleep maintenance and total sleep time in patients with RLS and comorbid insomnia [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3569669127">
         <span class="h3">
          Gabapentin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
         has not been as well studied in RLS as
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         and
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         , but the available data and clinical experience suggest that its effects are similar.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – We suggest beginning
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         at 100 to 300 mg in the evening (eg, one to two hours before the usual onset of symptoms) and titrating slowly upwards based on response and tolerability, particularly in older adults. The usual effective dose is 900 to 2400 mg daily given in a single dose or divided as one-third an hour before symptoms commence and two-thirds before bed. Especially in doses above 1200 mg, the administered dose may not correlate well with serum levels because of nonlinear kinetics.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – Common dose-related side effects of
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         include somnolence, dizziness, and ataxia. These effects can be minimized by starting with a low dose and titrating slowly. As with other drugs in this class, clinicians should be aware of risks and safety concerns related to suicidality, respiratory depression, and misuse and abuse. (See
         <a class="local">
          'Gabapentinoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         –
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
         , mean dose 733 mg/day, was effective in a four-week, open-label study of nine patients with idiopathic RLS [
         <a href="#rid58">
          58
         </a>
         ], and at a much higher mean dose (1855 mg) in a randomized, placebo-controlled trial of 22 patients [
         <a href="#rid59">
          59
         </a>
         ]. Although this trial suggested that mean gabapentin doses of 1800 mg a day are needed for maximal symptom benefit, many patients appear to benefit from a lower dose. Among dialysis patients, low-dose gabapentin (200 to 300 mg three times weekly after hemodialysis) was effective in a 12-week, double-blind crossover study [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2561042403">
         <span class="h3">
          Gabapentin enacarbil
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          Gabapentin enacarbil
         </a>
         is a prodrug of
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         that is converted to gabapentin after absorption and enables more consistent single daily dose administration. For the purposes of RLS, which tends to peak in the evenings, the dose is typically timed at about 5 PM to achieve target therapeutic levels at bedtime [
         <a href="#rid7">
          7
         </a>
         ]. It is preferred over other alpha-2-delta agonists in patients with symptoms during the day and night based on consistent pharmacokinetic properties.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The suggested starting dose of
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         for RLS is 600 mg, taken in the early evening (eg, at 5 PM). A lower starting dose (300 mg) is recommended in older adults. Although regulatory approval is only for the 600 mg dose, trials and clinical experience support titration up to 1200 mg as needed [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – Common adverse effects associated with
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         include somnolence and dizziness; these are generally mild to moderate and remit with time. In a 52-week, open-label study, two-thirds of patients reported mild to moderate side effects, leading to treatment discontinuation in 10 percent [
         <a href="#rid61">
          61
         </a>
         ]. Somnolence, dizziness, and weight gain were among the most common reasons for discontinuation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Several randomized, placebo-controlled studies have demonstrated that
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         is effective in reducing RLS symptom severity [
         <a href="#rid2">
          2,52,53,62-64
         </a>
         ]. In the largest study of 325 patients, gabapentin enacarbil at a dose of 600 or 1200 mg/day was associated with a 3- to 4-point improvement in IRLS scores compared with placebo [
         <a href="#rid63">
          63
         </a>
         ]. In another randomized study, gabapentin enacarbil also showed efficacy in decreasing the polysomnographic parameters of wake time during sleep and number of periodic limb movements with arousals per hour of sleep [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1663842">
         <span class="h2">
          Dopamine agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         The non-ergot dopamine agonists,
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         , and
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         , are effective in the treatment of RLS at low doses and are all considered reasonable first-line therapies for chronic persistent RLS in patients with an increased risk for side effects from gabapentinoids [
         <a href="#rid7">
          7
         </a>
         ]. Efficacy is similar among the three agents, and selection of a specific drug is typically based on patient preference with regard to route of administration (oral versus transdermal delivery), cost and formulary considerations, and whether or not daytime symptoms are present.
        </p>
        <p>
         Among dopaminergic therapies, the non-ergot dopamine agonists have a longer half-life and lower risk of augmentation compared with levodopa [
         <a href="#rid65">
          65,66
         </a>
         ]. The older ergot dopamine agonists (
         <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">
          bromocriptine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">
          cabergoline
         </a>
         , pergolide) have short-term efficacy but are no longer used to treat RLS due to risks of cardiac valvular disease and other fibrotic reactions [
         <a href="#rid1">
          1,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3352204905">
         <span class="h3">
          Administration and efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical effects of the three dopamine agonists are similar.
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          Ropinirole
         </a>
         and
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         should be avoided in patients with hepatic failure, as they are metabolized by the liver, and all three are renally excreted and require caution and/or dose modifications in patients with moderate to severe renal impairment.
        </p>
        <p>
         All dopamine agonists should be used at the minimum dose required to control symptoms and not exceeding dose ranges in the table in order to reduce the risk of augmentation  (
         <a class="graphic graphic_table graphicRef101364" href="/z/d/graphic/101364.html" rel="external">
          table 3
         </a>
         ). Doses required for RLS are lower than those used to treat Parkinson disease. Side effects common to all three agents are discussed below. (See
         <a class="local">
          'Side effects and monitoring'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pramipexole
         </strong>
         –
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          Pramipexole
         </a>
         immediate release (IR) is one of two oral dopamine agonists used in the treatment of RLS. A long-acting formulation exists but is not well studied in RLS.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dosing
         </strong>
         – The recommended starting dose of
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         IR is 0.125 mg once daily  (
         <a class="graphic graphic_table graphicRef101364" href="/z/d/graphic/101364.html" rel="external">
          table 3
         </a>
         ). Time to peak blood level is 120 minutes, and therefore the dose should be taken about two hours before the usual start of symptoms [
         <a href="#rid7">
          7
         </a>
         ]. The dose can be increased by 0.125 mg every two to three days depending on response and tolerability. Most patients require 0.5 mg or less for clinical benefit [
         <a href="#rid49">
          49,67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Efficacy
         </strong>
         – The benefit of
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         IR was demonstrated in a meta-analysis of seven randomized placebo-controlled trials totaling over 1200 patients [
         <a href="#rid2">
          2
         </a>
         ]. In all of the studies, pramipexole improved RLS symptom severity, with an average improvement in the IRLS score of 6.7 points over placebo (95% CI 4.9-8.5) [
         <a href="#rid2">
          2
         </a>
         ]. For reference, a 6-point difference has been proposed as a clinically meaningful improvement in IRLS scores [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Uncontrolled studies with longer-term follow-up (26 to 52 weeks) have reported a mean improvement of 17 points on the IRLS [
         <a href="#rid69">
          69,70
         </a>
         ]. In a large multicenter trial of two doses of
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         compared with
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         and placebo, 0.25 mg pramipexole was no more effective than placebo but 0.5 mg reduced the IRLS score more than placebo and had an equivalent effect to that of pregabalin [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ropinirole
         </strong>
         – Like
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         IR,
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         IR is an oral dopamine agonist used in the treatment of RLS. The long-acting formulation of ropinirole is not well studied in RLS.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dosing
         </strong>
         – The recommended starting dose of
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         IR is 0.25 mg once daily  (
         <a class="graphic graphic_table graphicRef101364" href="/z/d/graphic/101364.html" rel="external">
          table 3
         </a>
         ). Time to peak blood level is 90 minutes, and therefore the dose should be taken about 90 minutes before the usual start of symptoms [
         <a href="#rid7">
          7
         </a>
         ]. The dose may be increased by 0.25 mg every two to three days until relief is obtained. Most patients require at least 2 mg, and doses up to 4 mg may be needed. The maximum recommended dose is 3 mg in patients with end-stage kidney disease on hemodialysis. In one large randomized controlled trial, the average daily dose of ropinirole was 1.9 mg [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Efficacy
         </strong>
         – The benefit of
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         was demonstrated in a meta-analysis of five randomized placebo-controlled trials totaling over 900 patients, in which the average improvement in IRLS score over placebo was 4 points (95% CI 2-6) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rotigotine
         </strong>
         –
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          Rotigotine
         </a>
         is a non-ergot dopamine agonist that is formulated as a 24-hour transdermal patch. It is typically reserved for use in patients with symptoms throughout the day, for whom 24-hour coverage would be beneficial, or for patients with augmentation on oral dopamine agonists. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dosing
         </strong>
         – Transdermal
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         is typically started at 1 mg/24 hours and titrated upwards to a maximum dose of 3 mg/24 hours. Application site reaction is the most common adverse effect of the patch formulation (not related to rotigotine itself per se), reported by 40 to 50 percent of patients. To decrease the risk of skin reactions, the manufacturer recommends rotating application sites, avoidance of direct sun exposure, and removal of the patch during magnetic resonance imaging.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Efficacy
         </strong>
         – The benefit of
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         for RLS was demonstrated in a meta-analysis of five randomized controlled trials totaling over 600 patients, in which the average improvement in IRLS score over placebo was 7 points (95% CI 5.6-8.4) [
         <a href="#rid2">
          2
         </a>
         ]. Two long-term follow-up studies (52 to 104 weeks) have reported a mean improvement of 15 to 17 points on the IRLS [
         <a href="#rid72">
          72-74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H717636854">
         <span class="h3">
          Side effects and monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common initial side effects of dopamine agonists are nausea, lightheadedness, and fatigue; these are usually mild and resolve within 10 to 14 days. Less frequent side effects include nasal stuffiness, constipation, insomnia, leg edema, and mental status changes (confusion, psychosis); these are reversible if the medication is stopped. Excessive daytime sleepiness can occur at higher doses and occasionally manifests as sudden, unexpected sleep attacks [
         <a href="#rid75">
          75
         </a>
         ]. These may be less common than in patients with Parkinson disease on higher doses of
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         Patients on continuous dopamine agonist therapy are also at risk for the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impulse control disorders
         </strong>
         – As first reported in patients with Parkinson disease, dopamine agonist therapy in patients with RLS may be associated with an increased risk of impulse control disorders such as pathologic gambling, compulsive eating and shopping, and compulsive inappropriate hypersexuality [
         <a href="#rid77">
          77,78
         </a>
         ]. The risk in patients with RLS is estimated to range from 6 to 17 percent [
         <a href="#rid78">
          78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4896.html" rel="external">
          "Initial pharmacologic treatment of Parkinson disease", section on 'Impulse control disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Augmentation
         </strong>
         – Augmentation, which refers to a worsening of RLS symptoms with increasing doses of medication, including earlier onset of symptoms, increased intensity of symptoms, shorter duration of drug action, or topographic spread of symptoms to the arms, is a common complication of long-term dopaminergic therapy in RLS that is discussed in more detail below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients on daily dopaminergic therapy should be reassessed regularly (eg, every 6 to 12 months) and screened for side effects and complications such as augmentation, which is a common complication of long-term dopaminergic therapy [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="local">
          'Augmentation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Doses of
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         and
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         should
         <strong>
          not
         </strong>
         generally exceed the limits given above and in the table  (
         <a class="graphic graphic_table graphicRef101364" href="/z/d/graphic/101364.html" rel="external">
          table 3
         </a>
         ) to avoid or reduce the risk of augmentation. In a United States prescription database study that included nearly 400,000 patients with RLS receiving treatment with dopamine agonists, 19 percent of patients were prescribed higher than recommended doses of dopamine agonists for RLS [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rebound
         </strong>
         – Emergence or recurrence of RLS symptoms can occur in the early morning or late at night. When this occurs in isolation, it may be due to a short duration of action of the drug. More commonly, it is one of the manifestations of augmentation [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Withdrawal syndrome
         </strong>
         – Dopamine agonist withdrawal syndrome can occur with abrupt discontinuation of dopamine agonist therapy. Symptoms, including anxiety, panic attacks, depression, sweating, nausea, pain, fatigue, dizziness, and drug craving, may last many months [
         <a href="#rid80">
          80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4896.html" rel="external">
          "Initial pharmacologic treatment of Parkinson disease", section on 'Dopamine agonist withdrawal syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1382491">
         <span class="h2">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         RLS is often a lifelong disease, but the optimal and safe duration of pharmacologic therapy has not been well established [
         <a href="#rid48">
          48
         </a>
         ]. Most of the supporting data are based on relatively short (≤12-week) randomized trials, with fewer long-term extension studies supporting efficacy for 6 to 12 months of therapy with either a dopamine agonist or
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         .
        </p>
        <p>
         In clinical practice, the most common problems that arise with long-term therapy are loss of efficacy and augmentation. (See
         <a class="local">
          'Augmentation'
         </a>
         below and
         <a class="local">
          'Refractory RLS'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1663954">
         <span class="h1">
          AUGMENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Augmentation is the main complication of long-term dopaminergic therapy for restless legs syndrome (RLS) [
         <a href="#rid32">
          32
         </a>
         ]. It refers to an overall increase in RLS symptom severity with increasing doses of medication, including earlier onset of symptoms, increased intensity of symptoms, shorter duration of drug action, or topographic (geographic) spread of symptoms to previously unaffected body parts, including the trunk and arms.
        </p>
        <p class="headingAnchor" id="H223807430">
         <span class="h2">
          Identification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Augmentation should be considered a possibility in the following circumstances [
         <a href="#rid32">
          32,81
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A maintained increase in symptom severity despite appropriate treatment
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A maintained increase in symptom severity following a dose increase, particularly if a dose reduction leads to an improvement in symptoms
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Earlier onset of symptoms in the afternoon/evening
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Topographic spread of symptoms to previously unaffected body parts (eg, arms)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shorter latency to symptom onset during the day when at rest
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shorter duration of action of the drug
        </p>
        <p>
        </p>
        <p>
         Four screening questions have been proposed to help identify augmentation in patients on dopaminergic therapy for RLS  (
         <a class="graphic graphic_table graphicRef109702" href="/z/d/graphic/109702.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         The differential diagnosis of augmentation includes end-of-dose rebound, tolerance, natural disease progression, and exacerbating factors  (
         <a class="graphic graphic_table graphicRef117709" href="/z/d/graphic/117709.html" rel="external">
          table 5
         </a>
         ). Symptom characteristics and response to dose changes can be used to distinguish among them. For example, augmentation should be distinguished from end-of-dose rebound, which can cause worsening symptoms in the early morning but does not generally involve spread to the arms, and natural progression of disease or exacerbating factors, which can cause worsening of symptoms and topographic spread that do not improve by reducing the dopaminergic load  (
         <a class="graphic graphic_table graphicRef117709" href="/z/d/graphic/117709.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2736956721">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Augmentation was first recognized in patients taking
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         . In a multicenter, open-label study using flexible dosing of levodopa (mean maximum daily dose, 311 mg), 60 percent of patients developed augmentation at a median time of 71 days into therapy, leading to treatment discontinuation in 12 percent [
         <a href="#rid82">
          82
         </a>
         ]. Augmentation was significantly more common in patients taking greater than or equal to 300 mg of levodopa daily (70 versus 35 percent).
        </p>
        <p>
         The risk of augmentation with dopamine agonists appears to be lower but not insignificant; it has been reported in 3 to 9 percent of patients taking
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         for one year [
         <a href="#rid49">
          49
         </a>
         ], about one-third of patients taking pramipexole for two years [
         <a href="#rid83">
          83
         </a>
         ], and 42 to 68 percent of patients taking pramipexole for 8 to 10 years [
         <a href="#rid75">
          75,84
         </a>
         ]. Fewer studies have been performed on
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         , but it appears that the short-term augmentation rate is similar to that of pramipexole. Augmentation has been reported in 2 to 9 percent of patients taking
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         for one year [
         <a href="#rid73">
          73,85,86
         </a>
         ] and 38 percent of those using rotigotine for five years (only clinically significant in 13 percent) [
         <a href="#rid87">
          87
         </a>
         ]. The definition of augmentation and the method of assessment (ie, retrospective or prospective) have varied across studies, and therefore direct comparisons are difficult.
        </p>
        <p>
         The risk of augmentation increases with higher daily doses, longer duration of use, and lower iron stores [
         <a href="#rid49">
          49,88,89
         </a>
         ]. Other risk factors for augmentation are not well known; in one study, augmentation was significantly more common in patients with a family history of RLS and in those who had no evidence of neuropathy on electromyography or nerve conduction studies [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         Using dopaminergic drugs on an intermittent basis rather than continuously may lower the risk of augmentation, although this has not been well studied. This is the rationale for use of levodopa in patients with intermittent RLS, despite the high risk of augmentation with continuous use. (See
         <a class="local">
          'Carbidopa-levodopa'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          Tramadol
         </a>
         has also been reported to cause augmentation in some patients [
         <a href="#rid25">
          25
         </a>
         ]. Gabapentinoids have not been associated with augmentation.
        </p>
        <p class="headingAnchor" id="H2413507821">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Consensus-based guidelines for the management of augmentation when it is recognized in patients on dopamine agonists include the following  (
         <a class="graphic graphic_algorithm graphicRef116031" data-inline-graphics="116031" href="/z/d/graphic/116031.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid32">
          32
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Re-evaluate iron
         </strong>
         – Iron stores should be re-evaluated and iron replacement initiated if stores are low. Ferritin is the most useful test of iron stores but is an acute phase reactant and can be elevated independent of iron stores. Alternative studies to evaluate for iron deficiency in the setting of acute illness, inflammation, or malignancy are reviewed separately. (See
         <a class="local">
          'Iron replacement'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Review concomitant medications and sleep
         </strong>
         – Patients should be asked about lifestyle changes or new medications that may be exacerbating symptoms. (See
         <a class="local">
          'Nonpharmacologic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjust dosing
         </strong>
         – For mild augmentation, the dose of a dopamine agonist can be split between a nighttime dose and a dose earlier in the day  (
         <a class="graphic graphic_algorithm graphicRef116031" href="/z/d/graphic/116031.html" rel="external">
          algorithm 2
         </a>
         ). If this is ineffective, the dose can be modestly increased, but caution should be used not to exceed the maximum recommended total daily dosage  (
         <a class="graphic graphic_table graphicRef101364" href="/z/d/graphic/101364.html" rel="external">
          table 3
         </a>
         ). In addition, the patient should be carefully followed to ensure that augmentation is not worsening.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Change formulation
         </strong>
         – For more severe augmentation, switching from
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         or
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         to the extended-release transdermal preparation,
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         , can sometimes help, as the rate of significant augmentation may be less with rotigotine. Extended-release formulations of oral pramipexole and oral ropinirole also exist but have not yet been well studied in RLS [
         <a href="#rid91">
          91
         </a>
         ]. This strategy may be especially helpful if augmentation is predominantly manifested by early morning recurrence of RLS symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Discontinue dopamine agonist
         </strong>
         – Alternatively, dopamine agonists can be discontinued and replaced with gabapentinoids  (
         <a class="graphic graphic_algorithm graphicRef116031" href="/z/d/graphic/116031.html" rel="external">
          algorithm 2
         </a>
         ). We typically introduce the new drug and increase the dose to an effective level before slowly reducing the dopamine agonist and discontinuing if at all possible. Some experts advocate a 10-day wash-out period before introducing the alpha-2-delta ligand in order to establish a baseline measure of disease severity, but this can result in increased RLS symptoms and profound insomnia during the wash-out period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Add adjunctive therapy
         </strong>
         – For severe, continuous symptoms despite these measures, a low dose of a long-acting opioid may be an option in selected patients. (See
         <a class="local">
          'Opioids'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1663961">
         <span class="h1">
          REFRACTORY RLS
         </span>
        </p>
        <p class="headingAnchor" id="H4048082203">
         <span class="h2">
          Definition and general approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Refractory restless legs syndrome (RLS) is defined as restless legs unresponsive to monotherapy with tolerable doses of a dopamine agonist or alpha-2-delta ligand due to reduced efficacy, augmentation, or adverse effects.
        </p>
        <p>
         In patients with refractory symptoms, iron stores should be re-evaluated and iron replacement initiated if stores are low. Lifestyle practices, concomitant medications, and treatment adherence should also be reviewed. Additional sleep disorders, such as obstructive sleep apnea, should be considered, especially for patients living alone or who present with a disproportionate degree of sleep fragmentation, insomnia, or excessive sleepiness. Augmentation should be considered in patients on dopamine agonist therapy, particularly in patients requiring high daily doses. (See
         <a class="local">
          'Iron replacement'
         </a>
         above and
         <a class="local">
          'Avoidance of aggravating factors'
         </a>
         above and
         <a class="local">
          'Augmentation'
         </a>
         above.)
        </p>
        <p>
         Referral to a specialist for RLS management should be considered for these patients [
         <a href="#rid42">
          42
         </a>
         ]. The main pharmacologic treatment options are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use a combination of agents, such as a dopamine agonist, gabapentinoid, and/or a benzodiazepine. (See
         <a class="local">
          'Dopamine agonists'
         </a>
         above and
         <a class="local">
          'Gabapentinoids'
         </a>
         above and
         <a class="local">
          'Benzodiazepines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Change to a low-dose opioid. (See
         <a class="local">
          'Opioids'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16188985">
         <span class="h2">
          Opioids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Opioids can be effective in the treatment of chronic and refractory RLS, particularly for patients who have not responded to other therapies. The mechanism of action is not known, but an interaction between spinal opioid and dopamine receptors has been speculated [
         <a href="#rid92">
          92
         </a>
         ], and symptoms of RLS are a common feature of opioid withdrawal [
         <a href="#rid93">
          93
         </a>
         ]. Although low-potency opioids such as
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          tramadol
         </a>
         and
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         can be tried, most patients with refractory symptoms will require a high-potency agent such as
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         or
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         We typically restrict use to patients with more severe symptoms who fail to respond to other agents and who maintain regular follow-up to monitor for response and toxicity. Potential side effects include constipation, nausea, fatigue, itchiness, sweating, unsteadiness, depression, and exacerbation of sleep apnea.
        </p>
        <p>
         In order to promote appropriate and safe use of opioids in patients with refractory RLS, an expert consensus panel endorses the following guidelines [
         <a href="#rid94">
          94
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Before initiating opioid therapy, assess patients for the risk of opioid use disorder. State prescription drug monitoring programs should be queried, and a urine drug screen should be performed. (See
         <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">
          "Use of opioids in the management of chronic non-cancer pain", section on 'Evaluation of risk prior to initiating therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inform patients about expectations of treatment, the goals of therapy, and the risks of opioids [
         <a href="#rid95">
          95
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">
          "Use of opioids in the management of chronic non-cancer pain", section on 'Setting patient responsibilities, expectations, and treatment goals'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consider use of a written opioid agreement or contract. (See
         <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">
          "Use of opioids in the management of chronic non-cancer pain", section on 'Opioid agreement/consent form'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Schedule regular follow-up to assess effectiveness of therapy, side effects, and evidence for development of opioid use disorder. Review state prescription drug monitoring programs regularly and consider urine drug screening at least annually, especially in high-risk patients.
        </p>
        <p>
        </p>
        <p>
         When opioid therapy is selected, the choice of a specific agent should be individualized based on patient factors, physician preference, and cost. An initial trial of a low-potency opioid is often reasonable, although many patients will require a high-potency agent. Importantly, the usual effective doses of high-potency opioids for RLS are far lower than those used for treatment of chronic pain, and high doses should raise concern for misuse or diversion.
        </p>
        <p>
         In patients with RLS, longer-acting and controlled-release formulations may be preferred at night, as short-acting opioids may not give adequate length of coverage and may be associated with end-of-dose rebound of RLS symptoms, which may further disturb sleep [
         <a href="#rid94">
          94
         </a>
         ]. The Centers for Disease Control and Prevention (CDC) advises that opioid-naïve patients should not be started on extended-release/long-acting opioids as initial therapy for chronic pain, and extended-release/long-acting opioids should only be started in patients who have been taking opioids for at least one week [
         <a href="#rid96">
          96
         </a>
         ]. This practice may also be reasonable in patients with RLS. Treatment should begin at the lowest dose provided below, with the usual effective dose ranges for RLS provided in parentheses [
         <a href="#rid42">
          42,94
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low-potency opioids or opioid agonists:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          Codeine
         </a>
         30 mg (60 to 180 mg)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          Tramadol
         </a>
         (immediate release) 50 mg (50 to 100 mg)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          Tramadol
         </a>
         (extended release) 100 mg (100 to 200 mg)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High-potency opioids:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          Morphine
         </a>
         controlled release 10 or 15 mg (15 to 45 mg)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          Oxycodone
         </a>
         (immediate or extended release) 5 mg (10 to 30 mg)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">
          Hydrocodone
         </a>
         (immediate or extended release) 10 mg (20 to 45 mg)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          Methadone
         </a>
         2.5 mg (5 to 20 mg)
        </p>
        <p>
        </p>
        <p>
         Evidence to support the efficacy of opioids for RLS consists of case series and a small number of randomized trials [
         <a href="#rid94">
          94
         </a>
         ]. The quality of the evidence is limited by short-term follow-up in many studies, heterogeneous outcome assessment, and loss to follow-up.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a double-blind, multicenter trial of 304 patients with refractory RLS, controlled-release
         <a class="drug drug_general" data-topicid="89423" href="/z/d/drug information/89423.html" rel="external">
          oxycodone-naloxone
         </a>
         (not available in the United States) was more effective than placebo at 12 weeks in the 204 patients who completed the 12-week efficacy period (mean difference in International Restless Legs Syndrome Study Group rating scale [IRLS] scores: 8.15; 95% CI 5.5-10.8) [
         <a href="#rid97">
          97
         </a>
         ]. The mean daily dose of
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         was 22 mg. Benefit was preserved over a 40-week, open-label extension period that included 197 patients. Fatigue and constipation were the most common side effects; two patients developed ileus or sub-ileus. No augmentation was seen. Thirteen percent of patients taking oxycodone-naloxone during the randomized phase discontinued the study due to side effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A blinded, four-week crossover study of 11 patients with refractory RLS found that
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         (mean dose 16 mg/day) was superior to placebo with regard to number of sleep arousals, periodic leg movement frequency, and sleep efficiency [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A long-term retrospective study of 113 patients treated with opioids demonstrated persistent benefit, but a small number of patients developed sleep apnea [
         <a href="#rid99">
          99
         </a>
         ]. In a 10-year, open-label study of
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         for RLS, 15 percent of 76 patients discontinued methadone treatment in the first year, but the remainder continued to use it with benefit [
         <a href="#rid84">
          84
         </a>
         ]. The mean daily dose after six months was 10 mg, with subsequent increases of no more than 10 mg.
        </p>
        <p>
        </p>
        <p>
         In the United States, a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.massgeneral.org%2Frls-registry&amp;token=5yLNPmHjkOhvnhOBCCm6DPT2Udv8GO%2FTQObageKcy2Mp6QKt%2BY3o1EH%2FtAQL40hCrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=88241" target="_blank">
          National RLS Opioid Registry
         </a>
         has been created to help assess the long-term safety and efficacy of opioids for RLS. Information for patients and prescribers is available on the website [
         <a href="#rid100">
          100
         </a>
         ]. In the first report of 500 participants (median age 65 years, 57 percent female),
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         was the most commonly reported opioid (46 percent), followed by
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         (24 percent) and
         <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">
          hydrocodone
         </a>
         (14 percent) [
         <a href="#rid101">
          101
         </a>
         ]. The median total daily dose of opioid was 30
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         milligram equivalents (MME), and approximately one-third of the cohort reported an increase in opioid dose over the first year of registry follow-up. By year two, among 448 patients remaining in the registry, 41 percent of patients reported an increase in dose since study entry, and 42 percent of patients remained on the same dose and type of opioid [
         <a href="#rid102">
          102
         </a>
         ]. The mean daily MME for the cohort was 38.4 at baseline and 43.5 at year two. Factors associated with an increase of &gt;25 MME over the study period included stopping a dopamine agonist or gabapentinoid therapy, switching opioids, high baseline RLS symptom severity, use of opioids for comorbid pain, and a history of depression.
        </p>
        <p class="headingAnchor" id="H16189277">
         <span class="h2">
          Other drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other drugs that may be useful in RLS but have been reported in only a small number of (mainly open-label) studies include
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         (mean dose 236 mg/day) [
         <a href="#rid103">
          103
         </a>
         ],
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         (0.05 mg/day) [
         <a href="#rid104">
          104
         </a>
         ], and
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         (up to 300 mg/day) [
         <a href="#rid105">
          105
         </a>
         ]. Cannabis has been described as beneficial for RLS in case reports but has not been studied systematically [
         <a href="#rid106">
          106
         </a>
         ]. There is inadequate evidence to suggest that magnesium supplementation is an effective treatment for RLS [
         <a href="#rid107">
          107
         </a>
         ].
         <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">
          Dipyridamole
         </a>
         , a nucleoside transporter inhibitor with antiplatelet and pro-adenosine effects, may be useful based on a two-week placebo-controlled cross-over study in 29 patients with previously untreated RLS, but longer studies in a more varied patient population are needed [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
         Vitamin D deficiency has been associated with an increased risk of RLS in several observational studies [
         <a href="#rid109">
          109,110
         </a>
         ]. It is not yet known, however, whether vitamin D supplementation improves symptoms.
        </p>
        <p class="headingAnchor" id="H160086463">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H160086519">
         <span class="h2">
          Pregnancy and lactation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of restless legs syndrome (RLS) during pregnancy should be individualized based on symptom severity, comorbidities such as depression or anxiety, and patient preferences.
        </p>
        <p>
         Many patients can be managed successfully with education, reassurance, iron supplementation if indicated, and nonpharmacologic strategies. Pharmacologic therapies such as
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         may be considered for severe symptoms in women who wish to try medication. (See
         <a class="medical medical_review" href="/z/d/html/98366.html" rel="external">
          "Restless legs syndrome during pregnancy and lactation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H160086484">
         <span class="h2">
          End-stage kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of RLS in patients with end-stage kidney disease is similar to that in patients with normal kidney function. However, medication doses may need to be adjusted, especially if the patient is not yet receiving dialysis, as most dopamine agonists and alpha-2-delta ligands are excreted by the kidneys  (
         <a class="graphic graphic_table graphicRef101364" href="/z/d/graphic/101364.html" rel="external">
          table 3
         </a>
         ). Transdermal
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         is a notable exception. Careful attention to iron status is especially important in patients with end-stage kidney disease [
         <a href="#rid111">
          111
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16197.html" rel="external">
          "Sleep disorders in end-stage kidney disease", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1663989">
         <span class="h1">
          PERIODIC LIMB MOVEMENT DISORDER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Periodic limb movements of sleep (PLMS) accompany many sleep and neurologic disorders, including restless legs syndrome (RLS), obstructive sleep apnea (OSA), rapid eye movement (REM) sleep behavior disorder, narcolepsy, and Parkinson disease. PLMS increase in frequency with age. (See
         <a class="medical medical_review" href="/z/d/html/4892.html" rel="external">
          "Clinical features and diagnosis of restless legs syndrome and periodic limb movement disorder in adults", section on 'Periodic limb movements of sleep'
         </a>
         .)
        </p>
        <p>
         PLMS do not have a consistent relationship with symptoms (eg, insomnia, excessive daytime sleepiness) or with polysomnographic variables of sleep disruption. They are generally considered to be an age-related phenomenon, a response to arousals, or an epiphenomenon of other disorders. However, occasionally they occur abundantly with frequent electroencephalographic arousals in the absence of other disorders, leading the clinician to suspect that they are directly responsible for complaints of excessive sleepiness or insomnia. The term periodic limb movement disorder (PLMD) should be restricted to this subgroup.
        </p>
        <p>
         For patients with PLMS associated with RLS, treatment should concentrate on the symptoms of RLS rather than on the leg movements. For PLMS associated with other sleep disorders, independent treatment of PLMS is rarely required.
        </p>
        <p>
         There are limited data regarding management of PLMD. Polysomnographic studies of PLMS in RLS have shown reduction in the periodic limb movement index with
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         ,
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         , and
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         [
         <a href="#rid2">
          2,64,112,113
         </a>
         ]. A comparison study suggested greater reduction with pramipexole compared with pregabalin [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         Extrapolating from this data, we suggest a trial of dopamine agonist therapy in suspected cases of PLMD. If there are contraindications to dopamine agonist therapy, an alpha-2-delta ligand can be tried. Dosing and safety considerations are the same as for use in RLS. (See
         <a class="local">
          'Dopamine agonists'
         </a>
         above and
         <a class="local">
          'Gabapentinoids'
         </a>
         above.)
        </p>
        <p>
         If the primary symptoms of insomnia or sleepiness do not respond to adequate doses of the selected drug, then the patient should be re-evaluated for other causes of insomnia or excessive daytime sleepiness. (See
         <a class="medical medical_review" href="/z/d/html/7676.html" rel="external">
          "Evaluation and diagnosis of insomnia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14892.html" rel="external">
          "Approach to the patient with excessive daytime sleepiness"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          Clonazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , and
         <a class="drug drug_general" data-topicid="9883" href="/z/d/drug information/9883.html" rel="external">
          selegiline
         </a>
         have been reported to help PLMD in small, uncontrolled studies [
         <a href="#rid2">
          2
         </a>
         ]. It would appear, however, that clonazepam reduces arousals rather than eliminates PLMS. Longitudinal polysomnographic interventional studies using well-defined and unanimous scoring criteria and endpoints on PLMS are needed [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H58059705">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112949.html" rel="external">
          "Society guideline links: Restless legs syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1663996">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16243.html" rel="external">
          "Patient education: Restless legs syndrome (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/17181.html" rel="external">
          "Patient education: Nocturnal (nighttime) leg cramps (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Online information and support is available for patients with RLS through
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.rls.org%2F&amp;token=bvhiNvboZByLg75vNseaJaLYfbwJvMY0kXNup02%2Beqs%3D&amp;TOPIC_ID=88241" target="_blank">
          The Restless Legs Syndrome Foundation
         </a>
         and the American Academy of Sleep Medicine (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsleepeducation.org%2F&amp;token=%2BzKbA5HB2%2FbZMpueyFB0%2Blu8zF8ltxGZ7%2BaheeD%2BApqJ%2FU7evOOIT7s0BtfHAz67&amp;TOPIC_ID=88241" target="_blank">
          sleepeducation.org
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3182686167">
         <span class="h1">
          PATIENT PERSPECTIVE TOPICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/139684.html" rel="external">
          "Patient perspective: Severe restless legs syndrome and associated depression"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/140004.html" rel="external">
          "Patient perspective: Restless legs syndrome first apparent during pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1664003">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of therapy
         </strong>
         – Restless legs syndrome (RLS) is a treatable condition that generally responds well to pharmacologic therapy. The goals of therapy are to reduce or eliminate symptoms of RLS and improve daytime function, sleep, and quality of life. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Check iron stores
         </strong>
         – Iron stores should be evaluated in all patients with RLS  (
         <a class="graphic graphic_algorithm graphicRef131282" href="/z/d/graphic/131282.html" rel="external">
          algorithm 1
         </a>
         ). For patients with iron deficiency or low-normal ferritin levels (ie, serum ferritin &lt;75 ng/mL), we suggest a trial of oral iron therapy  (
         <a class="graphic graphic_table graphicRef106069" href="/z/d/graphic/106069.html" rel="external">
          table 6
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Unless symptoms are severe, we replete low iron stores before initiating a first-line medication. (See
         <a class="local">
          'Iron replacement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intravenous iron is generally reserved for patients with a serum ferritin ≤100 ng/mL and either a malabsorption state, complete intolerance to oral iron preparations, or moderate to severe symptoms despite a trial of oral iron, or the need for a more rapid response due to severity of symptoms. (See
         <a class="local">
          'Administration of iron'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Any adult with iron deficiency (eg, serum ferritin level &lt;30 ng/mL) should be evaluated for the underlying cause, which may include gastrointestinal blood loss, especially for adults over 40 to 50 years, or a condition that interferes with iron absorption  (
         <a class="graphic graphic_algorithm graphicRef131023" href="/z/d/graphic/131023.html" rel="external">
          algorithm 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Search for source of blood and iron loss'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Behavioral strategies
         </strong>
         – Patients should be counseled to avoid aggravating drugs and substances such as caffeine  (
         <a class="graphic graphic_table graphicRef88603" href="/z/d/graphic/88603.html" rel="external">
          table 2
         </a>
         ). Mental alerting activities, exercise, leg massage, and applied heat often help RLS  (
         <a class="graphic graphic_table graphicRef138393" href="/z/d/graphic/138393.html" rel="external">
          table 1
         </a>
         ). In patients with mild and/or intermittent symptoms, these therapies may be sufficient for symptom relief. (See
         <a class="local">
          'Nonpharmacologic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          On-demand therapy for intermittent symptoms
         </strong>
         – In patients with intermittent symptoms that are not frequent enough to require daily therapy but are nonetheless disabling when they do occur (eg, long car rides, occasional bedtime flares), we suggest a trial of
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         on an as-needed basis (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). One 25/100 mg tablet (or half a tablet) has rapid onset, good tolerability, and is unlikely to cause augmentation when used in this manner. (See
         <a class="local">
          'Intermittent symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First-line daily medication
         </strong>
         – In most patients with chronic persistent RLS (ie, symptoms ≥2 days per week and significantly impacting quality of life), we suggest initial therapy with a gabapentinoid (
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , or
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         ) rather than a dopamine agonist (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). While both classes of medications are more effective than placebo, we prefer to start with a gabapentinoid to avoid the risk of augmentation and impulse control disorders with dopamine agonists. Doses are provided in the table  (
         <a class="graphic graphic_table graphicRef101364" href="/z/d/graphic/101364.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Choice of therapy'
         </a>
         above and
         <a class="local">
          'Gabapentinoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A dopamine agonist (
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         , or
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         ) is a reasonable first-line alternative in patients at increased risk for side effects from a gabapentinoid, such as those with obesity and its complications, a past or present history of moderate or severe depression, disorders causing gait instability or respiratory failure, or a history of substance use disorder  (
         <a class="graphic graphic_algorithm graphicRef131282" href="/z/d/graphic/131282.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Dopamine agonists'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Options for refractory RLS
         </strong>
         – When RLS symptoms are refractory to first-line therapy with a gabapentinoid or a dopamine agonist, treatment options include combination therapy with drugs from different classes and a trial of low-dose opioids. Iron stores, exacerbating drugs and substances  (
         <a class="graphic graphic_table graphicRef88603" href="/z/d/graphic/88603.html" rel="external">
          table 2
         </a>
         ), and behavioral strategies  (
         <a class="graphic graphic_table graphicRef138393" href="/z/d/graphic/138393.html" rel="external">
          table 1
         </a>
         ) should also be reviewed. (See
         <a class="local">
          'Refractory RLS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of
         </strong>
         <strong>
          augmentation
         </strong>
         – Augmentation refers to an overall worsening of symptom severity while taking a dopaminergic medication for RLS. It is the most common complication of long-term dopaminergic therapy  (
         <a class="graphic graphic_table graphicRef109702" href="/z/d/graphic/109702.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef117709" href="/z/d/graphic/117709.html" rel="external">
          table 5
         </a>
         ). Management generally involves reduction or elimination of the causative agent and substitution of other medications  (
         <a class="graphic graphic_algorithm graphicRef116031" href="/z/d/graphic/116031.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Augmentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Periodic limb movement disorder
         </strong>
         – Treatment of periodic limb movement disorder (PLMD) as an entity distinct from RLS is not well studied, but the approach is similar to that of RLS. Periodic limb movements of sleep (PLMS) in the absence of insomnia or excessive daytime sleepiness do not require treatment. (See
         <a class="local">
          'Periodic limb movement disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H178534403">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate would like to acknowledge Robert Sheon, MD, and Daniel Tarsy, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Scholz H, Trenkwalder C, Kohnen R, et al. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev 2011; :CD006009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep 2012; 35:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilt TJ, MacDonald R, Ouellette J, et al. Pharmacologic therapy for primary restless legs syndrome: a systematic review and meta-analysis. JAMA Intern Med 2013; 173:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trotti LM, Becker LA. Iron for the treatment of restless legs syndrome. Cochrane Database Syst Rev 2019; 1:CD007834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2016; 87:2585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med 2018; 41:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silber MH, Buchfuhrer MJ, Earley CJ, et al. The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clin Proc 2021; 96:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trenkwalder C, Winkelmann J, Oertel W, et al. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Mov Disord 2017; 32:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho YW, Allen RP, Earley CJ. Efficacy of ferric carboxymaltose (FCM) 500 mg dose for the treatment of Restless Legs Syndrome. Sleep Med 2018; 42:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barton JC, Wooten VD, Acton RT. Hemochromatosis and iron therapy of Restless Legs Syndrome. Sleep Med 2001; 2:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Malo C, Miranda C, Novo Ponte S, et al. Low risk of iron overload or anaphylaxis during treatment of restless legs syndrome with intravenous iron: a consecutive case series in a regular clinical setting. Sleep Med 2020; 74:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, O'Reilly B, Venkataraman R, et al. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Med 2009; 10:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis BJ, Rajput A, Rajput ML, et al. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000; 43:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen RP, Adler CH, Du W, et al. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med 2011; 12:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho YW, Allen RP, Earley CJ. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Med 2016; 25:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bae H, Cho YW, Kim KT, et al. Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia. Sleep Med 2021; 84:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sloand JA, Shelly MA, Feigin A, et al. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004; 43:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Earley CJ, Horská A, Mohamed MA, et al. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 2009; 10:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 2009; 24:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell UH. Nondrug-related aspect of treating Ekbom disease, formerly known as restless legs syndrome. Neuropsychiatr Dis Treat 2011; 7:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chenini S, Barateau L, Guiraud L, et al. Cognitive strategies to improve symptoms of restless legs syndrome. J Sleep Res 2023; 32:e13794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aukerman MM, Aukerman D, Bayard M, et al. Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2006; 19:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lettieri CJ, Eliasson AH. Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial. Chest 2009; 135:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva C, Peralta AR, Bentes C. The urge to move and breathe - the impact of obstructive sleep apnea syndrome treatment in patients with previously diagnosed, clinically significant restless legs syndrome. Sleep Med 2017; 38:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoque R, Chesson AL Jr. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med 2010; 6:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008; 43:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nofzinger EA, Fasiczka A, Berman S, Thase ME. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry 2000; 61:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu XM, Liu Y, Jia SY, et al. Complementary and alternative therapies for restless legs syndrome: An evidence-based systematic review. Sleep Med Rev 2018; 38:158.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration (FDA) device classification under section 513(f)(2)(de novo) available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN220059 (Accessed on October 26, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogan RK, Roy A, Kram J, et al. Efficacy and safety of tonic motor activation (TOMAC) for medication-refractory restless legs syndrome: a randomized clinical trial. Sleep 2023; 46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy A, Ojile J, Kram J, et al. Long-term efficacy and safety of tonic motor activation for treatment of medication-refractory restless legs syndrome: A 24-Week Open-Label Extension Study. Sleep 2023; 46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 2016; 21:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Earley CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996; 19:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993; 43:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999; 52:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scholz H, Trenkwalder C, Kohnen R, et al. Levodopa for restless legs syndrome. Cochrane Database Syst Rev 2011; :CD005504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trenkwalder C, Stiasny K, Pollmächer T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995; 18:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med 1996; 100:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montplaisir J, Godbout R, Boghen D, et al. Familial restless legs with periodic movements in sleep: electrophysiologic, biochemical, and pharmacologic study. Neurology 1985; 35:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montagna P, Sassoli de Bianchi L, Zucconi M, et al. Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand 1984; 69:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Read DJ, Feest TG, Nassim MA. Clonazepam: effective treatment for restless legs syndrome in uraemia. Br Med J (Clin Res Ed) 1981; 283:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004; 79:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howell MJ, Schenck CH. Restless nocturnal eating: a common feature of Willis-Ekbom Syndrome (RLS). J Clin Sleep Med 2012; 8:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauerma H. Nocturnal wandering caused by restless legs and short-acting benzodiazepines. Acta Psychiatr Scand 1991; 83:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002; 3:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlos K, Prado GF, Teixeira CD, et al. Benzodiazepines for restless legs syndrome. Cochrane Database Syst Rev 2017; 3:CD006939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho T, Jimenez A, Sanchez I, et al. Sleep-related eating disorder associated with zolpidem: cases compiled from a literature review. Sleep Med X 2020; 2:100019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 2013; 14:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 2014; 370:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelmann J, Allen RP, Högl B, et al. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§. Mov Disord 2018; 33:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iftikhar IH, Alghothani L, Trotti LM. Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. Eur J Neurol 2017; 24:1446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009; 72:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009; 32:159.
          </a>
         </li>
         <li class="breakAll">
          https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodman CW, Brett AS. A Clinical Overview of Off-label Use of Gabapentinoid Drugs. JAMA Intern Med 2019; 179:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Borreguero D, Larrosa O, Williams AM, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology 2010; 74:1897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Borreguero D, Patrick J, DuBrava S, et al. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep 2014; 37:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Happe S, Klösch G, Saletu B, Zeitlhofer J. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology 2001; 57:1717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002; 59:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001; 38:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellenbogen AL, Thein SG, Winslow DH, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol 2011; 34:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee DO, Buchfuhrer MJ, Garcia-Borreguero D, et al. Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome. Sleep Med 2016; 19:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 2011; 7:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelman JW, Bogan RK, Schmidt MH, et al. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord 2011; 26:2065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trenkwalder C, Benes H, Grote L, et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 2007; 22:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassetti CL, Bornatico F, Fuhr P, et al. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. Swiss Med Wkly 2011; 141:w13274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006; 67:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trenkwalder C, Kohnen R, Allen RP, et al. Clinical trials in restless legs syndrome--recommendations of the European RLS Study Group (EURLSSG). Mov Disord 2007; 22 Suppl 18:S495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue Y, Kuroda K, Hirata K, et al. Long-term open-label study of pramipexole in patients with primary restless legs syndrome. J Neurol Sci 2010; 294:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Partinen M, Hirvonen K, Jama L, et al. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study). Sleep Med 2008; 9:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004; 75:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oertel WH, Benes H, Garcia-Borreguero D, et al. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med 2008; 9:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Högl B, Oertel WH, Stiasny-Kolster K, et al. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC Neurol 2010; 10:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esteve V, Carneiro J, Salazar G, et al. Effects of rotigotine on clinical symptoms, quality of life and sleep hygiene adequacy in haemodialysis-associated restless legs syndrome. Nefrologia (Engl Ed) 2018; 38:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med 2012; 13:1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stiasny K, Möller JC, Oertel WH. Safety of pramipexole in patients with restless legs syndrome. Neurology 2000; 55:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tippmann-Peikert M, Park JG, Boeve BF, et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007; 68:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornelius JR, Tippmann-Peikert M, Slocumb NL, et al. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010; 33:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelman JW. High national rates of high-dose dopamine agonist prescribing for restless legs syndrome. Sleep 2022; 45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 2013; 30:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Borreguero D, Stillman P, Benes H, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol 2011; 11:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Högl B, García-Borreguero D, Kohnen R, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 2010; 257:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004; 5:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 2011; 12:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue Y, Hirata K, Hayashida K, et al. Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beneš H, García-Borreguero D, Ferini-Strambi L, et al. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med 2012; 13:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oertel W, Trenkwalder C, Beneš H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011; 10:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frauscher B, Gschliesser V, Brandauer E, et al. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep Med 2009; 10:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li YS, Yeh WC, Hsu CY. Association of low serum ferritin levels with augmentation in patients with restless legs syndrome: A systematic review and meta-analysis. Sleep Med 2023; 112:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004; 61:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maestri M, Fulda S, Ferini-Strambi L, et al. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease. Sleep Med 2014; 15:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trenkwalder C, Zieglgänsberger W, Ahmedzai SH, Högl B. Pain, opioids, and sleep: implications for restless legs syndrome treatment. Sleep Med 2017; 31:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarter SJ, Labott JR, Mazumder MK, et al. Emergence of restless legs syndrome during opioid discontinuation. J Clin Sleep Med 2023; 19:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silber MH, Becker PM, Buchfuhrer MJ, et al. The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome. Mayo Clin Proc 2018; 93:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin M. Shared Medical Decision Making in Consideration of Opioid Therapy in a Patient With Restless Legs Syndrome. Continuum (Minneap Minn) 2017; 23:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep 2016; 65:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trenkwalder C, Beneš H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 2013; 12:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walters AS, Wagner ML, Hening WA, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993; 16:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walters AS, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001; 16:1105.
          </a>
         </li>
         <li class="breakAll">
          National RLS Opioid Registry https://www.massgeneral.org/rls-registry/.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelman JW, Purks J, Wipper B. Baseline and 1-year longitudinal data from the National Restless Legs Syndrome Opioid Registry. Sleep 2021; 44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelman JW, Wipper B, Zackon J. Long-term Safety, Dose Stability, and Efficacy of Opioids for Patients With Restless Legs Syndrome in the National RLS Opioid Registry. Neurology 2023; 100:e1520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Telstad W, Sørensen O, Larsen S, et al. Treatment of the restless legs syndrome with carbamazepine: a double blind study. Br Med J (Clin Res Ed) 1984; 288:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner ML, Walters AS, Coleman RG, et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996; 19:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evidente VG, Adler CH, Caviness JN, et al. Amantadine is beneficial in restless legs syndrome. Mov Disord 2000; 15:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghorayeb I. Cannabis for Restless Legs Syndrome. Adv Exp Med Biol 2021; 1297:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall NS, Serinel Y, Killick R, et al. Magnesium supplementation for the treatment of restless legs syndrome and periodic limb movement disorder: A systematic review. Sleep Med Rev 2019; 48:101218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Borreguero D, Garcia-Malo C, Granizo JJ, Ferré S. A Randomized, Placebo-Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome. Mov Disord 2021; 36:2387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wali S, Alsafadi S, Abaalkhail B, et al. The Association Between Vitamin D Level and Restless Legs Syndrome: A Population-Based Case-Control Study. J Clin Sleep Med 2018; 14:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oran M, Unsal C, Albayrak Y, et al. Possible association between vitamin D deficiency and restless legs syndrome. Neuropsychiatr Dis Treat 2014; 10:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannaki CD, Hadjigeorgiou GM, Karatzaferi C, et al. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. Kidney Int 2014; 85:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010; 11:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riccardi S, Ferri R, Garbazza C, et al. Pharmacological responsiveness of periodic limb movements in patients with restless legs syndrome: a systematic review and meta-analysis. J Clin Sleep Med 2023; 19:811.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 88241 Version 69.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21412893" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Dopamine agonists for restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22851801" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23460396" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pharmacologic therapy for primary restless legs syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30609006" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Iron for the treatment of restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27856776" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29425576" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34218864" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The Management of Restless Legs Syndrome: An Updated Algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28643901" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29458749" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Efficacy of ferric carboxymaltose (FCM) 500 mg dose for the treatment of Restless Legs Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11311689" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Hemochromatosis and iron therapy of Restless Legs Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32841843" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Low risk of iron overload or anaphylaxis during treatment of restless legs syndrome with intravenous iron: a consecutive case series in a regular clinical setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19230757" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10686463" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21978726" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27823710" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34157632" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15042543" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18280205" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19489063" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21654870" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Nondrug-related aspect of treating Ekbom disease, formerly known as restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36447357" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cognitive strategies to improve symptoms of restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16951298" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Exercise and restless legs syndrome: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19017878" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29031750" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The urge to move and breathe - the impact of obstructive sleep apnea syndrome treatment in patients with previously diagnosed, clinically significant restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20191944" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18468624" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Restless legs syndrome as side effect of second generation antidepressants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11105739" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28886918" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Complementary and alternative therapies for restless legs syndrome: An evidence-based systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28886918" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Complementary and alternative therapies for restless legs syndrome: An evidence-based systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37458698" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Efficacy and safety of tonic motor activation (TOMAC) for medication-refractory restless legs syndrome: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37439365" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Long-term efficacy and safety of tonic motor activation for treatment of medication-refractory restless legs syndrome: A 24-Week Open-Label Extension Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27448465" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9085489" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8094897" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Dopaminergic treatment of restless legs and rebound phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9932945" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21328278" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Levodopa for restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8560135" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8629680" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3965987" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Familial restless legs with periodic movements in sleep: electrophysiologic, biochemical, and pharmacologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6380197" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clonazepam and vibration in restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6793161" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clonazepam: effective treatment for restless legs syndrome in uraemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15244390" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : An algorithm for the management of restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22893772" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Restless nocturnal eating: a common feature of Willis-Ekbom Syndrome (RLS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1679281" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Nocturnal wandering caused by restless legs and short-acting benzodiazepines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14592194" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Amnestic sleep-related eating disorder associated with zolpidem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28319266" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Benzodiazepines for restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33870172" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Sleep-related eating disorder associated with zolpidem: cases compiled from a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23859128" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24521108" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Comparison of pregabalin with pramipexole for restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29756335" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28888061" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19188575" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19238802" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19238802" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30907944" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A Clinical Overview of Off-label Use of Gabapentinoid Drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20427750" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24899755" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11706121" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Treatment of idiopathic restless legs syndrome (RLS) with gabapentin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12451200" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11431189" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21242741" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A 52-week study of gabapentin enacarbil in restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27198947" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21677899" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21611981" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17274039" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22101745" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16931507" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Efficacy and safety of pramipexole in restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17530666" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Clinical trials in restless legs syndrome--recommendations of the European RLS Study Group (EURLSSG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20451927" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18276187" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14707315" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18753003" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20920156" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29198453" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effects of rotigotine on clinical symptoms, quality of life and sleep hygiene adequacy in haemodialysis-associated restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23036265" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Long-term use of pramipexole in the management of restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11094127" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Safety of pramipexole in patients with restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17242339" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20120624" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34417810" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : High national rates of high-dose dopamine agonist prescribing for restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23686524" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Dopamine agonist withdrawal syndrome: implications for patient care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21352569" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Algorithms for the diagnosis and treatment of restless legs syndrome in primary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19756826" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14725821" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21239226" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23103551" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22503658" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Augmentation in the treatment of restless legs syndrome with transdermal rotigotine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21705273" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19200780" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37879259" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Association of low serum ferritin levels with augmentation in patients with restless legs syndrome: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364685" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Long-term treatment of restless legs syndrome with dopamine agonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24767724" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27964861" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Pain, opioids, and sleep: implications for restless legs syndrome treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36692170" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Emergence of restless legs syndrome during opioid discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29304922" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28777181" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Shared Medical Decision Making in Consideration of Opioid Therapy in a Patient With Restless Legs Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26987082" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24140442" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8341893" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11748742" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Long-term follow-up on restless legs syndrome patients treated with opioids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11748742" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Long-term follow-up on restless legs syndrome patients treated with opioids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32918469" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Baseline and 1-year longitudinal data from the National Restless Legs Syndrome Opioid Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36697248" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Long-term Safety, Dose Stability, and Efficacy of Opioids for Patients With Restless Legs Syndrome in the National RLS Opioid Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6419958" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Treatment of the restless legs syndrome with carbamazepine: a double blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8650464" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10752586" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Amantadine is beneficial in restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33537945" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Cannabis for Restless Legs Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31678660" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Magnesium supplementation for the treatment of restless legs syndrome and periodic limb movement disorder: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34137476" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : A Randomized, Placebo-Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29609719" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : The Association Between Vitamin D Level and Restless Legs Syndrome: A Population-Based Case-Control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24899811" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Possible association between vitamin D deficiency and restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24107848" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20813583" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36692194" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Pharmacological responsiveness of periodic limb movements in patients with restless legs syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
